Beam Therapeutics Plans to Engage FDA on Potential Approval Path
Enrollment in the 60 mg dose cohort is underway.
Related stories
UCAR: trading halted on Nasdaq — volatility pause (1:42 PM ET)
Nasdaq halted trading in UCAR (volatility pause) at 1:42 PM ET.
L impact | EQUITY | Oct 29, 2026, 05:43 PM UTC
Shell Raises Buyback Commitment to $5 Billion
Shell raised its repurchase commitment to $5 billion over approximately three months. Its U.S. depositary shares rose 2.41% to $107.72 at 11:55 a.m. ET on October 29.
M impact | EQUITY | Oct 29, 2026, 05:41 PM UTC
Chipotle Shares Rise 8.44% as Customer Traffic Improves
Chipotle shares rose 8.44% to $31.155 at noon ET on October 29, as investors welcomed improving customer traffic. The report also cites increasing labor costs.
M impact | EQUITY | Oct 29, 2026, 05:41 PM UTC
Linde Raises Full-Year Earnings Outlook as Shares Fall 1.43%
Linde lifted its full-year earnings forecast as electronics demand strengthened. Shares fell 1.43% to $500.88 at 11:54 a.m. ET on October 29.
M impact | EQUITY | Oct 29, 2026, 05:41 PM UTC
FTI Consulting Reports Record Q3 Revenue, Raises EPS Guidance
FTI Consulting said third-quarter revenue reached a record, adjusted EPS rose 48%, and it raised its full-year adjusted EPS guidance. Shares jumped 11.7% in afternoon trading.
M impact | EQUITY | Oct 29, 2026, 05:41 PM UTC
Polymarket Investigates Suspicious Trades on Israeli Election
A person familiar with the matter said the trades were well-timed and profitable. The investigation comes amid scrutiny of potential insider trading on prediction-market platforms.
L impact | EQUITY | Oct 29, 2026, 05:40 PM UTC